Orchid successfully completes Phase-I study of OCID 2987

03 Jan 2012 Evaluate

Orchid Chemicals & Pharmaceuticals (Orchid) has successfully completed in Europe a Phase-I trial of its orally administered phosphodiesterase 4 inhibitor (PDE4) molecule OCID 2987 positioned for the treatment of inflammatory disorders including chronic obstructive pulmonary disease (COPD).

The Phase-I study was conducted to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of OCID 2987 at escalating single or repeated doses on healthy male volunteers. OCID 2987 was well tolerated up to the highest doses administered in both single and repeat dose studies and did not demonstrate a potential for nausea/emesis, a common unacceptable side-effect with most PDE4 inhibitors. Also, there were no serious adverse events or any cardiac safety concerns reported in the study.

Orchid's drug discovery efforts are conducted through its wholly-owned subsidiary, Orchid Research Laboratories.

Orchid is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was incorporated in the year 1992 as a 100% export-oriented unit.

Orchid Pharma Share Price

872.75 7.60 (0.88%)
05-Dec-2025 15:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.25
Dr. Reddys Lab 1275.60
Cipla 1521.95
Zydus Lifesciences 932.15
Lupin 2102.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×